Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Eur J Neurosci. 2011 Nov;34(9):1378–1389. doi: 10.1111/j.1460-9568.2011.07874.x

Figure 6. βarrestin-1 or 2 deficiency does not alter HU-210-mediated ERK1/2 inactivation.

Figure 6

A, B) βarrestin-1 or 2 mice were administered HU-210 (0.25 mg/kg i.p.) and euthanized 60 min post-injection. The levels of pERK1/2 in dorsal striatal extracts prepared from either βarrestin-2 or βarrestin-1 KO mice or WT littermates were assessed by western analyses. Representative western blots and the corresponding densitometric analyses are shown. Data are mean ± S.E.M.; n = 4–5 mice for each treatment group. **p < 0.01 and *p < 0.05, vehicle versus HU-210 treatment within genotypes by two-way ANOVA.